Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Gorilla and King Portfolio Candidates -- Ignore unavailable to you. Want to Upgrade?

To: rushnomore who wrote (49082)	11/22/2001 12:07:05 PM
From: Cosmo Daisey	Respond to of 54805

rushnomore, Thanks for the link. Some of the data in this older document is no longer considered accurate but accurate enough to give an understanding of the field. Science is about discoveries rather than conclusions. cdaisey@ocean-is-flat-calm-gotta-go.com

To: rushnomore who wrote (49082)	11/24/2001 6:41:27 PM
From: Cosmo Daisey	Read Replies (1) \| Respond to of 54805

Chiron Corporation (CHIR) Announces Results Of Phase III Study Of Tifacogin In Severe Sepsis; Chiron Says Sepsis Drug Fails To Meet Primary Goal; CHIR Stock Is Down -8.98% On Wednesday At Market Close This is what i'm talkin about. VRTX qualifies as a gorilla candidate because they could have knocked out this drug candidate in phase one or even earlier in the design stage. Phase three means CHIR has already spent about two $billion on Tifacogin. VRTX can do two years of wet lab research in 24 hours insilico. Phase one is the place to knock out drug candidates before billions have been spent. cdaiseyPhD@cheap-research.com